| Nov 23 |
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
|
| Nov 21 |
Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024?
|
| Nov 19 |
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
|
| Nov 19 |
The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically
|
| Nov 18 |
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
|
| Nov 18 |
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
|
| Nov 14 |
BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats
|
| Nov 14 |
BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Nov 12 |
BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates
|
| Nov 12 |
BridgeBio Pharma GAAP EPS of -$0.86 beats by $0.09, revenue of $2.73M misses by $0.65M
|
